QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

IMVT

QT53Immunovant, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
35.34
+0.63+1.81%
OverviewShort InterestFilings
IMVTQT53Immunovant, Inc.·NASDAQ
OverviewShort InterestFilings
35.34+1.81%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand205.31M
Perf Week7.48%
Market Cap7.13BForward P/E-EPS next Y-2.54Insider Trans0.41%Shs Float-Perf Month34.42%
Enterprise Value6.22BPEG7.05EPS next Q-0.60Inst Own-Short Float-Perf Quarter49.43%
Income-509528484.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y32.81%
Sales-P/B8.29EPS next Y3.09%ROA-52.83%Short Interest-Perf YTD39.02%
Book/sh1.93P/C-EPS next 5Y-ROE-68.16%52W High36.28 -2.59%Perf Year130.83%
Cash/sh1.98P/FCF-EPS past 3/5Y-ROIC-62.50%52W Low14.32 146.79%Perf 3Y-
Dividend Est.-EV/EBITDA-12.33Sales past 3/5Y-Gross Margin0.00%Volatility2.53% 4.91%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM1.10%Oper. Margin0.00%ATR (14)1.62Perf 10Y-
Dividend Ex-Date-Quick Ratio9.09Sales Y/Y TTM-Profit Margin0.00%RSI (14)65.45Recom2.33
Dividend Gr. 3/5Y-Current Ratio9.09EPS Q/Q3.95%SMA207.38%Beta1.61Target Price45.00
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA5018.03%Rel Volume1.95Prev Close34.71
Employees362LT Debt/Eq0.00EarningsAug 10SMA20042.92%Avg Volume2.00MPrice35.34
IPO DateJun 21, 2019Option/ShortYes / YesEPS/Sales Surpr.-23.31% -Net Debt/EBITDA1.79Volume3,888,368Change1.81%
Analyst Ratings
DateActionAnalystRatingTarget
May-21-26ReiteratedH.C. Wainwright$51 → $40
Jan-06-26UpgradeWolfe ResearchPeer Perform → Outperform$50
Dec-18-25ReiteratedGuggenheimBuy$44 → $41
Oct-14-25InitiatedTruistHold$16
Apr-22-25DowngradeUBSBuy → Neutral
Jan-03-25DowngradeWolfe ResearchOutperform → Peer Perform
Sep-10-24ReiteratedH.C. Wainwright$51
Jun-03-24ReiteratedOppenheimerOutperform$46
May-30-24ReiteratedGuggenheimBuy$48
May-30-24ReiteratedPiper SandlerOverweight$57
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2026
3/31/2026
FY 2025
3/31/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
FY 2018
3/31/2018
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other767757
Research and Development457361213
Other Operating Expense000
Operating Income-533-438-270
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-28-25-11
Net Income Before Taxes-505-413-259
Income Taxes011
Consolidated Net Income-506-414-259
Net Income From Continuing Operations-506-414-259
Net Income-506-414-259
EPS (Recurring)-2.77-2.73-1.88
EPS (Basic, Before Extraordinaries)-2.77-2.73-1.88
EPS (Diluted)-2.77-2.73-1.88
EBITDA-505-413-259
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding182152138
Market Capitalization4,521——
Operating Lease Expense
———
Insider Trading Volume
$36.53$33.95$31.37$28.78$26.20● Close Price0.00M87.50M175.00M262.50M350.00MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Pande AtulDirectorJun 15 '26Option Exercise8.433,00025,290118,231Jun 16 12:00 AM
Pande AtulDirectorJun 15 '26Sale34.021,50051,030116,731Jun 16 12:00 AM
Fromkin Andrew J.DirectorMay 28 '26Option Exercise8.22393,2023,230,654296,333May 29 12:00 AM
Fromkin Andrew J.DirectorMay 28 '26Sale33.51221,9517,438,11174,382May 29 12:00 AM
Gloria MelanieChief Operating OfficerMay 20 '26Sale32.453,115101,072242,107May 22 12:00 AM
Pande AtulDirectorMay 20 '26Option Exercise8.4312,000101,160270,252May 20 12:00 AM
Pande AtulDirectorMay 20 '26Sale32.006,000192,000116,731May 20 12:00 AM
Susman Robert GrahamDirectorMay 01 '26Sale27.172,50267,97936,394May 01 12:00 AM
Girao TiagoChief Financial OfficerApr 23 '26Sale29.6225,760763,011247,596Apr 24 12:00 AM
Stout Jay SChief Technology OfficerApr 23 '26Sale29.622,75481,573251,685Apr 24 12:00 AM
Van Tuyl ChristopherChief Legal OfficerApr 08 '26Sale24.835,165128,247183,231Apr 10 12:00 AM
Gloria MelanieChief Operating OfficerApr 08 '26Sale24.838,722216,567245,222Apr 10 12:00 AM
Stout Jay SChief Technology OfficerApr 08 '26Sale24.8310,132251,578254,439Apr 10 12:00 AM
Venker EricChief Executive OfficerApr 02 '26Sale24.1014,229342,85419,561Apr 03 12:00 AM
Venker EricChief Executive OfficerApr 01 '26Option Exercise14.46737,50010,664,2501,106,250Apr 03 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR